A Study of A4I Antagonist in Patients With Relapsing Multiple Sclerosis.
NCT ID: NCT00104143
Last Updated: 2016-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2007-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition
NCT02598167
Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
NCT01006265
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
NCT01081782
POC-MD MRI-based Trial in Relapsing-remitting Multiple Scler
NCT01051817
A NIS Evaluating Injectable Treatments in Patients With Relapsing Multiple Sclerosis
NCT05344469
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
A4I Antagonist
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* relapsing multiple sclerosis patients with types 1-4 (established through McDonald criteria);
* \>=1 MS attack or a Gd-enhancing MRI lesion between 1 month and 1 year before enrollment;
* EDSS score of \<=6.5;
* inadequate response to approved treatment(Canada only).
Exclusion Criteria
* systemic corticosteroids within 1 month before enrollment;
* MS treatments (non-symptomatic) within specified periods before enrollment;
* an infection requiring systemic anti-infective treatment or vaccination with a live vaccine within 1 month before enrollment.
18 Years
59 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sofia, , Bulgaria
Sofia, , Bulgaria
Sofia, , Bulgaria
Sofia, , Bulgaria
Edmonton, Alberta, Canada
Vancouver, British Columbia, Canada
London, Ontario, Canada
Greenfield Park, Quebec, Canada
Hull, Quebec, Canada
Hradec Králové, , Czechia
Ostrava, , Czechia
Prague, , Czechia
Marburg, , Germany
Regensburg, , Germany
Tübingen, , Germany
Ulm, , Germany
Gdansk, , Poland
Lodz, , Poland
Lublin, , Poland
Szczecin, , Poland
Warsaw, , Poland
Moscow, , Russia
Moscow, , Russia
Nizhny Novgorod, , Russia
Saint Petersburg, , Russia
Saint Petersburg, , Russia
Banská Bystrica, , Slovakia
Bratislava, , Slovakia
Košice, , Slovakia
Nitra, , Slovakia
Barcelona, , Spain
Barcelona, , Spain
Madrid, , Spain
Málaga, , Spain
Seville, , Spain
Liverpool, , United Kingdom
Newcastle upon Tyne, , United Kingdom
Nottingham, , United Kingdom
Sheffield, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NN18344
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.